{"entity":{"id":"nct06088004","kind":"trial","name":"Phase Ⅰ/Ⅱ Clinical Study to Evaluate ABO2011 in Advanced Solid Tumors","aka":[],"tldr":"A phase 1/2 trial of Toripalimab in advanced solid tumours, run by Suzhou Abogen Biosciences Co., Ltd., now recruiting.","summary":"Phase Ⅰ/Ⅱ Clinical Study to Evaluate ABO2011 in Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT06088004 by Suzhou Abogen Biosciences Co., Ltd., with 218 participants planned, started 2023-09-28 and due to reach its primary completion in 2026-12-30. Interventions recorded: ABO2011 Injection and Toripalimab.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06088004","url":"https://clinicaltrials.gov/study/NCT06088004"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":["toripalimab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06088004","phase":"1/2","setting":"A Phase I/II Clinical Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics (PK/PD) and Preliminary Efficacy of ABO2011 Monotherapy or in Combination With Toripalimab in Patients With Advanced Solid Tumors","sponsor":"Suzhou Abogen Biosciences Co., Ltd.","enrolled":218,"outcomes":[]},"route":"/trials/nct06088004/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"drug":[{"id":"toripalimab","kind":"drug","name":"Toripalimab","route":"/drugs/toripalimab/"}]}}